LAURUSLABS Q3 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,195 Cr
verified against source
Revenue YoY
-23%
reported change
EBITDA
₹183 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Laurus Labs reported Q3 FY24 revenue of INR 1,195 crore, down 23% YoY, with EBITDA at INR 183 crore (15.3% margin). Excluding a large CDMO PO, revenue grew 6%. Gross margins remained resilient at 54.3%, demonstrating pricing power despite revenue pressure. The Formulation division delivered 47% YoY growth to INR 367 crore, driven by ARV recovery and developed market sales. However, CDMO revenues declined to INR 212 crore due to timing of customer contracts. The Bio division showed strong momentum with INR 42 crore revenue. Management remains committed to H2 FY24 being better than H1, projecting EBITDA margins moving "significantly" above 20% as volumes normalize. Key concerns include operating deleverage from fixed costs, delayed animal health ramp-up (1-2 quarters), and investor frustration over lack of quantitative guidance. New capacity investments (R3 facility, crop sciences, animal health) are progressing but will take 12-18 months to turn green. The company has invested ~INR 450 crore in non-CapEx initiatives (Bio, ImmunoACT, gene therapy) that are yet to fully monetise.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated commitment to H2 FY24 being better than H1 FY24, citing healthy order book and strong commercial execution expected from Q4 onwards.
- Management expects EBITDA margins to move from current ~15% to "definitely beyond 20%" as sales volumes increase, with most incremental gross margin flowing through to EBITDA.
- Current asset turn at 0.9x with 5-year average of 1.1x and peak of 1.4x. Revenue should scale with capacity utilisation improvement across CDMO, Bio, and FDF businesses.
- Full year R&D spend expected at 4.5% of sales, focused on pipeline enhancement including gene therapy initiatives. 61 products in R&D pipeline across various markets.
Risks flagged
- Analyst (Chetan Kapoor) directly challenged management on high scientist-to-project ratio (750 scientists for 60 projects vs industry average of 4-5 per project). Fixed costs not translating to revenues causing margin compression.
- Multiple analysts raised concerns about negative operating cash flow in Q3 and INR 500 crore increase in net debt to ~INR 2,500 crore. Management acknowledged discrepancy and committed to clarify/submit revised numbers to exchanges.
- Analyst (Rohit Jain) criticized repeated qualitative-only guidance over three quarters. Management declined to provide specific EBITDA margin targets despite gross margins at 54% and high fixed cost base.
- Management acknowledged FY20-FY21 historical comparison expected to repeat but provided no timeline. Three quarters of below-expectation results without quantitative recovery roadmap testing investor patience.
Key quotes
- We expect EBITDA margins from current little over 15% to definitely beyond 20%. We can't give you a number, but it will improve significantly.
- We are between INR 6 billion and INR 7 billion right now, and we expect to use maybe INR 1 billion more during this quarter because of the anticipated launches in U.S. And also increased demand coming from our CMO partner from Europe.
- The capacity required for ARV formulations is very less. So less than 20% of our capacity, 2 billion. I would not expect we'll use even 2 billion tablets.
- This is a very interesting question. It all depends on the stage and complexity of the projects being handled. If it is RSM, which may involve one or two steps, if it is intermediate, maybe six, seven steps. If it is API, it could involve additional steps.
Research modules